Atripla R/anti-TB combination in TB/HIV patients. Drug in focus

BMC Research Notes

Volumn 4, Issue , 2011, Pages

  Semvua, Hadija H ^a   Kibiki, Gibson S ^a  

^a KILIMANJARO CLINICAL RESEARCH INSTITUTE   (Tanzania)

Author keywords

Efavirenz; Emtricitabine; HIV; Interaction; Tenofovir; Tuberculosis

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS;

EID: 82055181758     PISSN: None     EISSN: 17560500     Source Type: Journal    
DOI: 10.1186/1756-0500-4-511     Document Type: Article

References (85)

1. Providing HIV care for co-infected tuberculosis patients: a perspective from sub-Saharan Africa. Harries AD, Zachariah R, Lawn SD, Int J Tuberc Lung Dis 2009 13 6 16 19105873
2. HIV seroprevalence by anonymous testing in patients with Mycobacterium tuberculosis and in tuberculosis contacts. Bowen EF, Rice PS, Cooke NT, Whitfield RJ, Rayner CF, Lancet 2000 356 1488 1489 10.1016/S0140-6736(00)02876-2 11081535
3. The double burden of HIV infection and tuberculosis in sub-Saharan Africa. Msamanga GI, Fawzi WW, N Engl J Med 1997 337 849 851 10.1056/NEJM199709183371210 9295244 (Pubitemid 27391638)
4. "An estimate of the contribution of HIV infection to the recent rise in tuberculosis in England and Wales: should all tuberculosis patients be routinely HIV tested?". Rose AM, Sinka K, Watson JM, Mortimer JY, Charlett A, Thorax 2002 57 442 445 10.1136/thorax.57.5.442 11978923 (Pubitemid 34494157)
5. Biopharmaceutics, pharmacokinetics pharmacodynamics of antituberculous drugs. Budha Nageshwar R, Lee Richard E, Meibohm Bernd, Curr Med Chem 2008 15 8
6. Updated guidelines for the use of ryfamycins for the treatment of tuberculosis among HIV-infected patients taking protease inhibitors or nonnucleoside reverse transcriptase inhibitors. http://www.cdc.gov/nchstp/tb/tb- hiv-drugs/toc.htm accessed June 25th 2009
7. Multi-drug-resistant Mycobacterium tuberculosis: molecular perspectives. Rattan A, et al. Emerg Infect Dis 1998 4 195 209 10.3201/eid0402.980207 9621190 (Pubitemid 28311206)
8. HIV transmission and primary drug resistance. Turner D, Wainberg MA, AIDS REV 2006 8 17 23 16736948
9. Pharmacokinetic interactions with Rifampicin: clinical relevance. Niemi Mikko, Backman Janne T, Fromm Martin F, et al. Clin pharmacokinet 2003 42 819 850 10.2165/00003088-200342090-00003 12882588 (Pubitemid 36995083)
10. Treatment of tuberculosis in HIV-infected persons in the era of highly active antiretroviral therapy. Dean GL, Edwards SG, Ives NJ, Matthews G, Fox EF, Navaratne L, Fisher M, Taylor GP, Miller R, Taylor CB, de Ruiter A, Pozniak AL, AIDS 2002 16 75 83 10.1097/00002030-200201040-00010 11741165 (Pubitemid 34062184)
11. Combined therapy for tuberculosis and HIV-1: the challenge for drug discovery. Pepper DJ, Meintjes GA, McIlleron H, Wilkinson RJ, Drug Discov Today 2007 12 980 989 10.1016/j.drudis.2007.08.001 17993418 (Pubitemid 350052669)
12. Pharmacokinetic interactions between nevirapine and rifampin. Robinson, et al. World AIDs conference Geneva Switzerland 1998
13. Coadministration of rifampin and nevirapine in HIV-infected patients with TB. Oliva J, Moreno S, Sanz J, et al. AIDS 2003 17 637 638 12598789 (Pubitemid 36293122)
14. Pharmacokinetic interaction between nevirapine and rifampicin in HIV-infected patients with tuberculosis. Ribera E, Pou L, Lopez RM, et al. J Acqui Immune Defic Syndr 2001 28 450 453 (Pubitemid 34033196)
15. Effect of rifampicin-based antitubercular Therapy on nevirapine plasma concentrations in South African adults with HIV-associatedtuberculosis. Cohen K, van CG, Boulle A, et al. J Antimicrob Chemother 2008 61 2 389 393 18096560
16. Pharmacokinetic interactions between efavirenz and rifampicin in HIV-infected patients with tuberculosis. Lopez-Cortes LF, Ruiz-Valderas R, Viciana P, et al. Clin Pharmacokinet 2002 41 681 690 10.2165/00003088-200241090- 00004 12126459
17. Efavirenz levels and 24-week efficacy in HIV-infected patients with tuberculosis receiving highly active antiretroviral therapy and rifampicin. Manosuthi W, Sungkanuparph S, Thakkinstian A, et al. AIDS 2005 19 1481 1486 10.1097/01.aids.0000183630.27665.30 16135901 (Pubitemid 41400693)
18. Decreased bioavailability of rifampin and other antituberculosis drugs in patients with advanced human immunodefficiency virus disease. Gurumurthy P, Ramachandran G, Hemanth Kumar AK, et al. Antimicrob Agents chemother 2004 48 4473 4475 10.1128/AAC.48.11.4473-4475.2004 15504887 (Pubitemid 39434921)
19. Determinants of rifampicin, isoniazid, pyrazinamide, and ethambutol pharmacokinetics in a cohort of tuberculosis patients. McIlleron H, Wash P, Burger A, Norman J, Folb PI, Smith P, Antimicrob Agents Chemother 2006 50 1170 7 10.1128/AAC.50.4.1170-1177.2006 16569826
20. Antiretroviral therapy in AIDS patients with tuberculosis. Moreno, et al. AIDs Rev 2006 8 115 124 17078482 (Pubitemid 44614029)
21. Immune restoration disease after the treatment of immunodeficient HIV-infected patients with highly active antiretroviral therapy. French MA, et al. HIV Med 2000 1 107 115 10.1046/j.1468-1293.2000.00012.x 11737333
22. Determinants of immune reconstitution inflammatory syndrome in HIV Type 1-Infected patients with tuberculosis after initiation of antiretroviral therapy. Breton G, et al. Clin Infect Dis 2004 39 1709 1712 10.1086/425742 15578375 (Pubitemid 39578550)
23. Paradoxical worsening of tuberculosis following antiretroviral therapy in patients with AIDS. Narita M, et al. Am J Respir Crit Care Med 1998 158 157 161 9655723 (Pubitemid 28337174)
24. Explosion of tuberculin-specific Th1-responses induce immune restoration syndrome in tuberculosis and HIV co-infected patients. Bourgarit A, et al. AIDS 2006 1 F7
25. Incidence and risk factors for immune reconstitution inflammatory syndrome during highly active antiretroviral therapy. Shelburne SA, et al. AIDS 2005 19 399 406 10.1097/01.aids.0000161769.06158.8a 15750393 (Pubitemid 40446186)
26. Treatment of tuberculosis in HIV-infected persons in the era of highly active antiretroviral therapy. Dean GL, et al. AIDS 2002 16 75 83 10.1097/00002030-200201040-00010 11741165 (Pubitemid 34062184)
27. Comparative pharmacokinetics and pharmacodynamics of the rifamycin antibacterials. Burman WJ, et al. Clin Pharmacokinet 2001 40 327 341 10.2165/00003088-200140050-00002 11432536 (Pubitemid 32565595)
28. An update and review of antiretroviral therapy. Piacenti FJ, Pharmacotherapy 2006 26 111 1133
29. Utility of tuberculosis directly observed therapy programs as sites for access to and provision of antiretroviral therapy in resource-limited countries. Friedland G, Abdool KS, Abdool KQ, Lalloo U, Jack C, Gandhi N, El Sadr W, Clin Infect Dis 2004 38 Suppl 5 421 S428 15156433
30. Pharmacological aspects of new antiretroviral drugs. Long MC, King JR, Acosta EP, Curr HIV/AIDS Rep 2009 6 43 57 10.1007/s11904-009-0007-y 19149996
31. Efavirenz/emtricitabine/tenofovir disoproxil fumaratefixed dose combination, first line therapy for all. Coicoechea M, Best B, Expert Opin Pharmacotherapy 2007 8 371 382 10.1517/14656566.8.3.371
32. Efavirenz/emtricitabine/tenofovir disoproxil fumarate: triple combination tablet. Frampton JE, Croom KF, Drugs 2006 66 1501 1512 10.2165/00003495- 200666110-00012 16906786
33. Emtricitabine: an antiretroviral agent for HIV infection. Bang LM, Scott LJ, Drugs 2003 63 241 242
34. Emtricitabine, a new antiretroviral agent with activity against HIV-1 and hepatitis B virus. Saag MS, Clin Infect Dis 2006 42 126 131 10.1086/498348 16323102 (Pubitemid 41832091)
35. Emtriva- package insert, Gilead Sciences. Foster City 2004
36. Lack of clinically relevant drug-drug interaction between tenofovir DF and rifampin in healthy volunteers. Droste J, Kearney B, Van Horssen P, Burger D, 5th International Workshop on clinical pharmacology of HIV therapy. Rome, Italy. April 1-3, 2004 2004 Abstract 4.11.
37. Viread-package insert, Gilead Sciences. Foster City, Calif 2001
38. Tenofovir disoproxil fumarate. Grim SA, Romanelli F, Ann Pharmacother 2003 37 849 859 12773076 (Pubitemid 36618375)
39. Tenofovir disoproxil fumarate: clinical pharmacology and pharmacokinetics. Kearney BP, Flaherty JF, Shah J, Clin Pharmacokinet 2004 43 595 612 10.2165/00003088-200443090-00003 15217303 (Pubitemid 38951802)
40. Quality of life, emotional status, and adherence of HIV-1-infected patients treated with efavirenz versus protease inhibitor-containing regimens. Fumaz CR, Tuldra A, Ferrer MJ, et al. J Acquir Immune Defic Syndr 2002 29 244 253 11873073 (Pubitemid 34208532)
41. Efavirenz 600 mg/day versus efavirenz 800 mg/day in HIV-infected patients with tuberculosis receiving rifampicin: 48 weeks results. Manosuthi W, Kiertiburanakul S, Sungkanuparph S, Ruxrungtham K, Vibhagool A, Rattanasiri S, et al. AIDS 2006 20 131 2 10.1097/01.aids.0000196181.18916.9b 16327334 (Pubitemid 41818129)
42. Efavirenz and rifampicin in the South African context: is there a need to dose-increase efavirenz with concurrent rifampicin therapy? Orrell C, Cohen K, Conradie F, Zeinecker J, Ive P, Sanne I, Wood R, Antivir Ther 2011 16 527 534 10.3851/IMP1780 21685540
43. Pharmacokinetic interactions between efavirenz and rifampicin in the treatment of HIV and tuberculosis: one size does not fit all. Brennan-Bonson P, Lyus R, Harrison T, Pakianathan M, Macallan D, AIDS 2005 19 1541 1543 10.1097/01.aids.0000183519.45137.a6 16135909 (Pubitemid 41400701)
44. Pharmacogenetics of efavirenz and central nervous system side effects:an Adults AIDS Clinical Trial Group Study. Haas DW, Ribaudo HJ, Kim RB, Tierney C, Wilkinson GR, Gulick RM, et al. AIDS 2004 18 2391 400 15622315 (Pubitemid 40065906)
45. Administration of efavirenz (600 mg/day) with rifampicin results in highly variable level but excellent clinical outcomes in patients treated for tuberculosis and HIV. Friedland G, Khoo S, Jack C, Lallo U, Antimicrob Agents Chemother 2006 58 1299 302 10.1093/jac/dkl399 (Pubitemid 44884158)
46. Impact of CYP2B6 polymorphism on hepatic efavirenz metabolism in vitro. Desta Z, Saussele T, Ward B, et al. Pharmacogenomics 2007 8 6 547 558 10.2217/14622416.8.6.547 17559344 (Pubitemid 46947859)
47. The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity. Ward BA, Gorski JC, Jones DR, et al. J Pharmacol Exp Ther 2003 306 287 300 10.1124/jpet.103. 049601 12676886 (Pubitemid 36734384)
48. Metabolism of efavirenz and 8-hydroxyefavirenz by P450 2B6 leads to inactivation by two distinct mechanisms. Bumpus NN, Kent UM, Hollenberg PF, J Pharmacol Exp Ther 2006 318 345 351 10.1124/jpet.106.102525 16611850
49. Homozygous CYP2B6 *6 (Q172H and K262R) correlates with high plasma efavirenz concentrations in HIV-1 patients treated with standard efavirenz-containing regimens. Tsuchiya K, Gatanaga H, Tachikawa N, et al. Biochem Biophys Res Commun 2004 319 1322 1326 10.1016/j.bbrc.2004.05.116 15194512 (Pubitemid 38759555)
50. Genetic variability of CYP2B6 in populations of African and Asian origin: allele frequencies, novel functional variants, and possible implications for anti-HIV therapy with efavirenz. Klein K, Lang T, Saussele T, et al. Pharmacogenet Genomics 2005 15 12 861 873 10.1097/01213011-200512000-00004 16272958 (Pubitemid 41666768)
51. A pharmacokinetic and pharmacogenetic study of efavirenz in children; dosing guidelines can result in sub-therapeutic concentrations. Heine Robter, et al. Antivir Therapy 2008 13 779 787
52. Influence of the cytochrome P450 2B6 genotype on population pharmacokinetics of efavirenz in human immunodeficiency virus patients. Cabrera SE, Santos D, Valverde MP, et al. Antimicrob Agents Chemother 2009 53 2791 2798 10.1128/AAC.01537-08 19433561
53. Pharmacogenetics-based population pharmacokinetic analysis of efavirenz in HIV-1-infected individuals. Arab-Alameddine M, Di Iulio J, Buclin T, et al. Clin Pharmacol Ther 2009 85 485 494 10.1038/clpt.2008.271 19225447
54. High prevalence of the CYP2B6 516 G - > T(*6) variant and effect on the population pharmacokinetics of efavirenz in HIV/AIDS outpatients in Zimbabwe. Nyakutira C, Roshammar D, Chigutsa E, et al. Eur J Clin Pharmacol 2008 64 357 365 10.1007/s00228-007-0412-3 18057928
55. Identification of a novel specific CYP2B6 allele in Africans causing impaired metabolism of the HIV drug efavirenz. Wang J, Sonnerborg A, Rane A, et al. Pharmacogenet Genomics 2006 16 191 198 16495778
56. Effect of rifampicin and CYP2B6 genotype on long-term efavirenz autoinduction and plasma exposure in HIV patients with or without tuberculosis. Ngaimisi E, Mugusi S, Minzi O, Sasi P, Riedel KD, Suda A, Ueda N, Janabi M, Mugusi F, Haefeli WE, Bertilsson L, Burhenne J, Aklillu E, Clin Pharmacol Ther 2011 90 406 413 10.1038/clpt.2011.129 21814190
57. Effects of CYP2B6 G516T polymorphisms on plasma efavirenz and nevirapine levels when co-administered with rifampicin in HIV/TB co-infected Thai adults. Uttayamakul S, Likanonsakul S, Manosuthi W, Wichukchinda N, Kalambaheti T, Nakayama EE, Shioda T, Khusmith S, AIDS Res Ther 2010 7 8 10.1186/1742-6405-7-8 20338069
58. Pharmacokinetics of efavirenz when co-administered with rifampin in TB/HIV co-infected patients: pharmacogenetic effect of CYP2B6 variation. Kwara A, Lartey M, Sagoe KW, Xexemeku F, Kenu E, Oliver-Commey J, Boima V, Sagoe A, Boamah I, Greenblatt DJ, Court MH, J Clin Pharmacol 2008 48 1032 1040 10.1177/0091270008321790 18728241
59. Once daily highly active antiretroviral therapy for HIV-1 infected children: safety and efficacy of an efavirenz containing regimen. Scherpbier HJ, Bekker V, et al. Pediatrics 2007 119 705 715 10.1542/peds.2006-1367 (Pubitemid 46407545)
60. Need for therapeutic drug monitoring in HIV-1 infected children receiving efavirenz doses according to international guidelines. von Hentig N, Koenigs C, Elanjikal S, et al. Eur J Med Res 2006 11 377 380 17101460 (Pubitemid 44575697)
61. High prevalence of subtherapeutic plasma concentrations of efavirenz in children. Ren Y, Nuttall JJ, Egbers C, et al. J Acquir Immune Defic Syndr 2007 45 133 136 10.1097/QAI.0b013e31805c9d52 17417100 (Pubitemid 46869804)
62. Efavirenz pharmacokinetics in HIV-1-infected children are associated with CYP2B6-G516T polymorphism. Saitoh A, Fletcher CV, Brundage R, et al. J Acquir Immune Defic Syndr 2007 45 280 285 17356468 (Pubitemid 47012374)
63. Pharmacokinetics and pharmacodynamics of efavirenz and nelfinavir in HIV-infected children participating in an area-under-the-curve controlled trial. Fletcher CV, Brundage RC, Fenton T, et al. Clin Pharmacol Ther 2008 83 300 306 10.1038/sj.clpt.6100282 17609682
64. Efavirenz in human breast milk, mothers', and newborns' plasma. Schneider S, Peltier A, Gras A, et al. J Acquir Immune Defic Syndr 2008 48 450 454 10.1097/QAI.0b013e31817bbc21 18614925
65. Tolerance of efavirenz in children. Teglas JP, Quartier P, Treluyer JM, et al. AIDS 2001 15 241 243 10.1097/00002030-200101260-00014 11216933 (Pubitemid 32142300)
66. Efavirenz plasma concentrations at 1, 3, and 6 months post-antiretroviral therapy initiation in HIV type 1-infected South African children. Viljoen M, Gous H, Kruger HS, Riddick A, Meyers TM, Rheeders M, AIDS Res Hum Retroviruses 2010 26 613 619 10.1089/aid.2009.0200 20507205
67. Are recommended dose of efavirenz optimal in young West African HIV-infected children? (ANRS 12103). Hirt D, Urien S, Olivier M, et al. Antimicrob Agents Chemother 2009 *Important report on suboptimal efavirenz exposure in African children
68. Pediatric under-dosing of efavirenz: a pharmacokinetic study in Uganda. Fillekes Q, et al. Advance online edition JAIDS 2011
69. Clinical management of tuberculosis in the context of HIV infection. De Jong BC, Israelski DM, Corbett EL, et al. Annu Rev Med 2004 55 283 301 10.1146/annurev.med.55.091902.103753 14746522 (Pubitemid 38316728)
70. The treatment of tuberculosis in HIV-infected persons. Pozniak AL, Miller R, Ormerod LP, AIDS 1999 13 435 45 10.1097/00002030-199903110-00001 10197371
71. Standard dose efavirenz vs standard dose nevirapine in antiretroviral regimens among HIV-1 and tuberculosis co-infected patients who receive rifampicin. Manosuthi W, Mankatitharm W, Lueangnivomkul A, et al. HIV Med 2008 9 294 299 10.1111/j.1468-1293.2008.00563.x 18400076 (Pubitemid 351517276)
72. The treatment of tuberculosis in HIV-infected persons. Pozniak AL, Miller R, Ormerod LP, AIDS 1999 13 435 45 10.1097/00002030-199903110-00001 10197371
73. Treatment of tuberculosis in HIV-infected patients: safety and antiretroviral efficacy of the concomitant use of ritonavir and rifampin. Moreno S, Podzamczer D, Blazquez R, et al. AIDS 2001 15 1185 1187 10.1097/00002030- 200106150-00018 11416725 (Pubitemid 32549874)
74. Pharmacokinetic interaction between rifampin and the combination of indinavir and low-dose ritonavir in HIV-infected patients. Justesen US, Andersen AB, Klitgaard NA, et al. Clin Infect Dis 2004 38 426 429 10.1086/380794 14727216 (Pubitemid 38200123)
75. Pharmacokinetics of adjusted-dose lopinavir-ritonavir combined with rifampin in healthy volunteers. La Porte CJ, Colbers EP, Bertz R, et al. Antimicrob Agents Chemother 2004 48 1553 60 10.1128/AAC.48.5.1553-1560.2004 15105105 (Pubitemid 38544359)
76. Effect of rifampin on steady-state pharmacokinetics of atazanavir with ritonavir in healthy volunteers. Burger DM, Agarwala S, Child M, et al. Antimicrob Agents Chemother 2006 50 3336 42 10.1128/AAC.00461-06 17005814 (Pubitemid 44527507)
77. Pharmacokinetic interaction between rifampicin and the once-daily combination of saquinavir and low-dose ritonavir in HIV-infected patients with tuberculosis. Ribera E, Azuaje C, Lopez RM, et al. J Antimicrob Chemother 2007 59 690 697 10.1093/jac/dkl552 17307771 (Pubitemid 47073403)
78. Combination of tenofovir and emtricitabine plus efavirenz in vitro modulation of ABC transporter and intracellular drug accumulation. Bousquet L, Pruvost A, Guvut AC, et al. Antimicrob agent Chemother 2009 53 896 902 10.1128/AAC.00733-08
79. Enfuvirtide, a new fusion inhibitor for therapy of humanimmunodeficiency virus infection. Hardy H, Skolnik PR, Pharmacotherapy 2004 24 198 211 10.1592/phco.24.2.198.33141 14998221 (Pubitemid 38209440)
80. Enfuvirtide, an HIV-1 fusion inhibitor, for drug resistant HIV infection in North and South America. Lalezari JP, Henry K, O'Hearn M, Montaner JS, Piliero PJ, Trottier B, et al. N Engl J Med 2003 348 2175 2185 10.1056/NEJMoa035026 12637625 (Pubitemid 36618128)
81. Efficacy of enfuvirtide in patients infected with drug resistance HIV-1 in Europe and Australia. Lazzarin A, Clotet B, Cooper D, Reyness J, Arasteh K, Nelson M, et al. N Engl J Med 2003 348 2175 2185 10.1056/NEJMoa035026 12637625 (Pubitemid 36618128)
82. Durable efficacy of enfuvirtide over 48 weeks in heavily treatment-experienced HIV-1 infected patients in the T-20 versus optimized background regimen only 1 and 2 clinical trials. Nelson M, Arasteh K, Clotet B, Cooper DA, Henry K, Katlama C, et al. J Acquir Immune Defic Syndr 2005 40 404 412 10.1097/01.qai.0000185314.56556.c3 16280694 (Pubitemid 41669173)
83. Concomitant use of an active boosted protease inhibitor with enfuvirtide in treatment-experienced HIV-1 infected individuals: recent data and consensus recommendations. Youle M, Staszweski S, Clotet B, Arribas JR, Blaxhult A, Carosi G, et al. HIV lin trials 2006 7 86 96 10.1310/2XVK-PBGL-735N-WH72 (Pubitemid 44082691)
84. Lack of interaction between enfuvirtide and ritonavir or ritonavir-boosted saquinavir in HIV-1-infected patients. Ruxrungtham K, Boyd M, Bellibas SE, et al. J Clin Pharmacol 2004 44 793 803 10.1177/0091270004266489 15199084 (Pubitemid 38765941)
85. Lack of enzyme-inducing effect of rifampicin on the pharmacokinetics of enfuvirtide. Boyd MA, Zhang X, Dorr A, Ruxrungtham K, et al. J Clin Pharmacol 2003 43 1382 1391 10.1177/0091270003259220 14615475 (Pubitemid 37433312)